Detalles de la búsqueda
1.
Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Catheter Cardiovasc Interv
; 98(4): 713-720, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33118696
2.
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
N Engl J Med
; 376(24): 2319-2328, 2017 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28402237
3.
Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
Catheter Cardiovasc Interv
; 95(1): 89-96, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30968559
4.
Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography.
Catheter Cardiovasc Interv
; 92(2): E106-E114, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29332307
5.
First-in-Man Trial of SiO2 Inert-Coated Bare Metal Stent System in Native Coronary Stenosisã- The AXETIS FIM Trial.
Circ J
; 82(2): 477-485, 2018 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28717068
6.
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
N Engl J Med
; 377(18): 1791-2, 2017 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29091563
7.
Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
Am Heart J
; 167(2): 133-40, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24439973
8.
First report on long-term clinical results after treatment of coronary bifurcation lesions with the Tryton dedicated bifurcation stent.
Catheter Cardiovasc Interv
; 84(5): 759-65, 2014 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25485348
9.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
EuroIntervention
; 17(16): 1340-1347, 2022 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34483094
10.
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial.
EuroIntervention
; 16(11): e904-e912, 2020 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31062692
11.
A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial.
Int J Cardiol
; 300: 93-98, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31511193
12.
The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy.
Int J Cardiovasc Imaging
; 36(4): 565-575, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31898006
13.
The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
Int J Cardiovasc Imaging
; 35(7): 1189-1198, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30911857
14.
Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial.
EuroIntervention
; 14(4): e434-e442, 2018 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29688175
15.
Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI.
EuroIntervention
; 14(4): e426-e433, 2018 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29786537
16.
Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
Expert Rev Med Devices
; 14(5): 325-334, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28402204
17.
Bioresorbable drug-eluting scaffolds for treatment of vascular disease.
Expert Opin Drug Deliv
; 13(5): 725-39, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26865247
18.
Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria.
EuroIntervention
; 12(5): e557-65, 2016 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27497355
19.
The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the Accuracy of Physiological Indices of Functional Stenosis Severity).
Circ Cardiovasc Interv
; 9(12)2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27899407
20.
Coronary Artery Vessel Healing Pattern, Short and Long Term, After Implantation of the Everolimus-Eluting Bioresorbable Vascular Scaffold.
J Am Heart Assoc
; 4(11)2015 Nov 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26553215